Related Experiment Video
Updated: Apr 3, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
Chandra Prakash Prasad1, Purusottam Mohapatra2, Tommy Andersson3
1Cell and Experimental Pathology, Department of Translational Medicine, Lund University, Clinical Research Centre, Skåne University Hospital, Malmö SE-20502, Sweden. Chandra.Prasad@med.lu.se.
Abstract:
In recent years, scientists have advocated the use of targeted therapies in the form of drugs that modulate genes and proteins that are directly associated with cancer progression and metastasis. Malignant melanoma is a dreadful cancer type that has been associated with the rapid dissemination of primary tumors to multiple sites, including bone, brain, liver and lungs. The discovery that approximately 40%-50% of malignant melanomas contain a mutation in BRAF at codon 600 gave scientists a new approach to tackle this disease. However, clinical studies on patients have shown that although BRAFi (BRAF inhibitors) trigger early anti-tumor responses, the majority of patients later develop resistance to the therapy. Recent studies have shown that WNT5A plays a key role in enhancing the resistance of melanoma cells to BRAFi. The focus of the current review will be on melanoma development, signaling pathways important to acquired resistance to BRAFi, and why WNT5A inhibitors are attractive candidates to be included in combinatorial therapies for melanoma.
Insights
Targeted therapies like BRAF inhibitors (BRAFi) show early promise for melanoma but often lead to resistance. WNT5A is identified as a key factor in this resistance, suggesting WNT5A inhibitors could improve melanoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant melanoma is an aggressive cancer known for rapid metastasis.
- Targeted therapies, including BRAF inhibitors (BRAFi), have been developed to combat melanoma.
- While BRAFi are effective initially, acquired resistance limits long-term patient benefit.
Purpose of the Study:
- To review melanoma development and BRAFi resistance mechanisms.
- To highlight the role of WNT5A in acquired resistance to BRAFi.
- To evaluate WNT5A inhibitors as potential combinatorial treatments for melanoma.
Main Methods:
- Review of recent scientific literature on melanoma, BRAFi, and WNT5A.
- Analysis of signaling pathways involved in BRAFi resistance.
- Discussion of the therapeutic potential of WNT5A inhibition.
Main Results:
- Approximately 40%-50% of melanomas harbor BRAF mutations, making them targets for BRAFi.
- WNT5A has been identified as a critical mediator of acquired resistance to BRAFi in melanoma cells.
- Combinatorial therapy involving WNT5A inhibitors may overcome BRAFi resistance.
Conclusions:
- Understanding melanoma progression and resistance pathways is crucial for effective treatment.
- WNT5A signaling is a significant contributor to BRAFi resistance in melanoma.
- Targeting WNT5A in combination with BRAFi presents a promising strategy for improving melanoma patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:54Canonical Wnt Signaling Pathway
01:41Non-Canonical Wnt Signaling Pathways
01:41Non-Canonical Wnt Signaling Pathways
02:56Treatment Resistant Cancers